A 76-year-old man is brought to the emergency department by his daughter because he has been feeling lightheaded and almost passed out during dinner. Furthermore, over the past few days he has been experiencing heart palpitations. His medical history is significant for well-controlled hypertension and diabetes. Given this presentation, an electrocardiogram is performed showing an irregularly irregular tachyarrhythmia with narrow QRS complexes. The patient is prescribed a drug that decreases the slope of phase 0 of the ventricular action potential but does not change the overall duration of the action potential. Which of the following drugs is consistent with this mechanism of action?
Q72
A 45-year-old male presents to your office with complaints of chronic insomnia. After reviewing his medical history, you decide to prescribe zolpidem. Which of the following is a valid reason to choose zolpidem over a benzodiazepine?
Q73
A 60-year-old man with a 1-year history of recurrent aspiration pneumonia is brought to the emergency department by his daughter after being found unconscious and gasping for air in his bed. Despite resuscitative efforts, the patient dies. Autopsy of the patient shows degeneration of the corticospinal tracts and anterior horn cells of the upper cervical cord. There is asymmetrical atrophy of the limb muscles, the diaphragm, and the intercostal muscles. Which of the following drugs would have most likely slowed the progression of this patient's condition?
Q74
A 38-year-old woman comes to the physician because of a 1-month history of palpitations. She does not smoke or drink alcohol. Her pulse is 136/min and irregularly irregular. An ECG shows irregularly spaced QRS complexes with no distinct P waves. Treatment is started with a drug that slows atrioventricular node conduction velocity and prevents voltage-dependent calcium entry into myocytes. The patient is at greatest risk for which of the following adverse effects?
Q75
An otherwise healthy 13-year-old boy is brought to the physician because of asthma attacks that have been increasing in frequency and severity over the past 4 weeks. He was first diagnosed with asthma 6 months ago. Current medications include high-dose inhaled fluticasone and salmeterol daily, with additional albuterol as needed. He has required several courses of oral corticosteroids. A medication is added to his therapy regimen that results in downregulation of the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Which of the following drugs was most likely added to the patient's medication regimen?
Q76
A 64-year-old man presents to his physician 6 months after experiencing a myocardial infarction. The patient currently denies any symptoms and is only in for a check up. The patient's past medical history is notable for diabetes (type II), obesity, hypertension and cyclothymia. His current medications are hydrochlorothiazide, metoprolol, metformin, insulin, fluoxetine, and fish oil. On physical exam you note a calm elderly man who is moderately obese and in no current distress. The patient's cardiovascular exam is notable for a S4 heart sound. The patients lab work is below.
Serum:
Na+: 140 mEq/L
Cl-: 100 mEq/L
K+: 4.4 mEq/L
HCO3-: 23 mEq/L
BUN: 20 mg/dL
Glucose: 120 mg/dL
Creatinine: 1.6 mg/dL
Ca2+: 10.1 mg/dL
AST: 11 U/L
ALT: 9 U/L
Cholesterol: 190 mg/dL
Triglycerides: 150 mg/dL
High density lipoprotein associated cholesterol: 11 mg/dL
Low density lipoprotein associated cholesterol: 149 mg/dL
The physician updates the patient's medication regimen after this visit.
The patient returns 2 weeks later and presents his blood glucose diary to you demonstrating a mean blood glucose of 167 mg/dL. He is also complaining of flushing that occurs occasionally but otherwise is doing well. Which of the following is most likely to alleviate this patient's current symptom?
Q77
A 50-year-old man presents to the emergency department for evaluation of a pulsatile headache, palpitations, chest pain, and anxiety. The vital signs include: heart rate 90/min, blood pressure 211/161 mm Hg, and respiration rate 18/min. His fundoscopic exam is remarkable for papilledema. An urgent urinalysis reveals increased protein and red blood cells (RBCs). Further evaluation reveals elevated plasma metanephrines. What is the 1st step in the definitive treatment of this patient’s underlying disorder?
Q78
A 26-year-old woman presents to the clinic with complaints of missing her 'monthlies'. She usually has her menses around the 15th of every month and they last for about 4 days. She is not on any birth control and has recently gotten into a relationship with her boyfriend from college. She is on lithium for maintenance therapy of her bipolar disorder. She once took herself off of lithium, but she became so depressed that she had a suicide attempt shortly after. She is concerned about how lithium use might affect her fetus if she were pregnant. What is the single most appropriate recommendation?
Q79
A 68-year-old man presents to his primary care physician with complaints of intermittent dysuria, pain with ejaculation, mild lower abdominal pain, and difficulty voiding for the last four months. There is no weight loss or change in stools. He has no known family history of cancer. His past medical history is notable for irritable bowel syndrome and hypertension. On examination, he is well-appearing but mildly uncomfortable. There are no abdominal or rectal masses appreciated; the prostate is mildly tender to palpation, but with normal size, texture, and contour. Urinalysis reveals trace leukocyte esterase and negative nitrite, negative blood, and no bacteria on microscopy. Which of the following is the most appropriate treatment?
Q80
A 75-year-old man with a seizure disorder is brought to the emergency department by a friend because of progressive confusion over the past two weeks. He is unable to provide any history. His vital signs are within normal limits. He appears lethargic and is only oriented to person. Oral mucosa is moist. There is no jugular venous distention. A basic metabolic panel shows a serum sodium concentration of 115 mEq/L but is otherwise normal. Serum osmolality is low and antidiuretic hormone level is elevated. X-ray of the chest shows no abnormalities. Which of the following is the most likely cause of this patient’s hyponatremia?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 71: A 76-year-old man is brought to the emergency department by his daughter because he has been feeling lightheaded and almost passed out during dinner. Furthermore, over the past few days he has been experiencing heart palpitations. His medical history is significant for well-controlled hypertension and diabetes. Given this presentation, an electrocardiogram is performed showing an irregularly irregular tachyarrhythmia with narrow QRS complexes. The patient is prescribed a drug that decreases the slope of phase 0 of the ventricular action potential but does not change the overall duration of the action potential. Which of the following drugs is consistent with this mechanism of action?
A. Procainamide
B. Mexiletine
C. Propranolol
D. Dofetilide
E. Propafenone (Correct Answer)
Explanation: ***Propafenone***
- **Propafenone** is a **Class IC antiarrhythmic drug** that strongly blocks fast **sodium channels**, thereby decreasing the slope of phase 0 depolarization.
- Class IC drugs significantly slow conduction velocity but have **minimal effect on action potential duration (APD)** or effective refractory period (ERP).
*Procainamide*
- **Procainamide** is a **Class IA antiarrhythmic drug**. It blocks sodium channels and also prolongs repolarization by blocking potassium channels.
- This prolongation of repolarization leads to an **increased action potential duration (APD)**, which is contrary to the question stem.
*Mexiletine*
- **Mexiletine** is a **Class IB antiarrhythmic drug**. It blocks sodium channels but with **fast on-off kinetics**, leading to minimal effect at normal heart rates.
- Class IB drugs typically **shorten the action potential duration (APD)**, especially in ischemic tissue, by blocking inactivated sodium channels and affecting potassium currents.
*Propranolol*
- **Propranolol** is a **Class II antiarrhythmic drug (beta-blocker)**. It primarily acts by blocking beta-adrenergic receptors, reducing automaticity and slowing AV nodal conduction.
- Beta-blockers affect phase 4 (spontaneous depolarization) and prolong the effective refractory period of the AV node, but they do not primarily decrease the slope of phase 0 of the ventricular action potential without changing APD.
*Dofetilide*
- **Dofetilide** is a **Class III antiarrhythmic drug**. It selectively blocks **potassium channels**, thereby *prolonging repolarization* and the action potential duration (APD).
- Prolongation of APD is a characteristic feature of Class III drugs, which is contrary to the drug mechanism described in the question.
Question 72: A 45-year-old male presents to your office with complaints of chronic insomnia. After reviewing his medical history, you decide to prescribe zolpidem. Which of the following is a valid reason to choose zolpidem over a benzodiazepine?
A. Zolpidem has a lower risk of tolerance and dependence (Correct Answer)
B. Zolpidem has a slow onset of action
C. Zolpidem is a potent anticonvulsant
D. Zolpidem does not bind to the GABA receptor
E. Zolpidem is a potent muscle relaxant
Explanation: ***Zolpidem has a lower risk of tolerance and dependence***
- While both zolpidem and benzodiazepines enhance GABAergic activity, **zolpidem** is a **selective GABAA receptor modulator** (specifically targeting the α1-subunit). This selectivity theoretically contributes to a lower risk of tolerance and dependence compared to non-selective benzodiazepines.
- Benzodiazepines, by binding to a broader range of GABA-A receptor subunits, are associated with a higher potential for **physical dependence**, **withdrawal symptoms**, and the need for dose escalation over time to achieve the same hypnotic effect (tolerance).
*Zolpidem has a slow onset of action*
- Zolpidem actually has a **rapid onset of action**, typically within 15-30 minutes, which is beneficial for initiating sleep.
- A slow onset would make it less effective for patients needing to fall asleep quickly.
*Zolpidem is a potent anticonvulsant*
- While zolpidem has some **sedative-hypnotic properties** similar to benzodiazepines, it is a relatively weak anticonvulsant and is not typically prescribed for controlling seizures.
- **Benzodiazepines** like clonazepam or lorazepam are well-established for their potent anticonvulsant effects.
*Zolpidem does not bind to the GABA receptor*
- This statement is incorrect; **zolpidem is a GABAA receptor agonist**, meaning it binds to a specific site on the GABAA receptor complex.
- Its mechanism of action involves enhancing the inhibitory effects of GABA, leading to sedation and sleep induction.
*Zolpidem is a potent muscle relaxant*
- Zolpidem possesses some **muscle relaxant properties**, similar to benzodiazepines, but these are generally less pronounced.
- **Benzodiazepines** are more commonly used for their significant muscle relaxant effects due to their broader interactions with GABAA receptor subunits throughout the central nervous system.
Question 73: A 60-year-old man with a 1-year history of recurrent aspiration pneumonia is brought to the emergency department by his daughter after being found unconscious and gasping for air in his bed. Despite resuscitative efforts, the patient dies. Autopsy of the patient shows degeneration of the corticospinal tracts and anterior horn cells of the upper cervical cord. There is asymmetrical atrophy of the limb muscles, the diaphragm, and the intercostal muscles. Which of the following drugs would have most likely slowed the progression of this patient's condition?
A. Inactivated virus vaccine
B. Corticosteroids
C. Glatiramer acetate
D. Riluzole (Correct Answer)
E. Nusinersen
Explanation: ***Riluzole***
- This patient's presentation with **recurrent aspiration pneumonia**, progressive muscle weakness, and eventual respiratory failure, along with autopsy findings of **degeneration of corticospinal tracts and anterior horn cells**, is highly suggestive of **amyotrophic lateral sclerosis (ALS)**.
- **Riluzole** is a glutamate inhibitor that is the only drug approved to extend survival and delay the need for tracheostomy in patients with ALS, primarily by reducing excitotoxic damage to motor neurons.
*Inactivated virus vaccine*
- An inactivated virus vaccine is used to prevent viral infections, and while aspiration pneumonia can be complicated by infections, it does not address the underlying **neurodegenerative process** described.
- Vaccinations, such as the flu vaccine, might prevent some types of pneumonia but would not slow the progression of a condition like ALS.
*Corticosteroids*
- **Corticosteroids** are potent anti-inflammatory and immunosuppressive agents often used in autoimmune diseases but are generally not effective and can even be detrimental in conditions like ALS due to potential side effects like myopathy.
- They have no proven benefit in altering the course or slowing the progression of ALS.
*Glatiramer acetate*
- **Glatiramer acetate** is an immunomodulator specifically used in the treatment of **multiple sclerosis (MS)**.
- It works by mimicking myelin basic protein and diverting immune responses away from myelin, a mechanism irrelevant to the pathophysiology of ALS.
*Nusinersen*
- **Nusinersen** is an antisense oligonucleotide used to treat **spinal muscular atrophy (SMA)**, a genetic motor neuron disease.
- While both ALS and SMA involve motor neuron degeneration, they are distinct conditions with different genetic and molecular pathology; Nusinersen is not indicated for ALS.
Question 74: A 38-year-old woman comes to the physician because of a 1-month history of palpitations. She does not smoke or drink alcohol. Her pulse is 136/min and irregularly irregular. An ECG shows irregularly spaced QRS complexes with no distinct P waves. Treatment is started with a drug that slows atrioventricular node conduction velocity and prevents voltage-dependent calcium entry into myocytes. The patient is at greatest risk for which of the following adverse effects?
A. Bronchospasm
B. Peripheral edema (Correct Answer)
C. Dry mouth
D. Tinnitus
E. Gingival hyperplasia
Explanation: ***Peripheral edema***
- The patient's symptoms (irregularly irregular pulse, no distinct P waves) suggest **atrial fibrillation**. The drug described, which slows AV nodal conduction velocity and prevents voltage-dependent calcium entry into myocytes, is a **non-dihydropyridine calcium channel blocker** such as **verapamil** or **diltiazem**.
- While **peripheral edema** occurs more commonly with **dihydropyridine calcium channel blockers** (e.g., nifedipine, amlodipine), it can also occur with **non-dihydropyridine CCBs** due to their **vasodilatory effects** on peripheral arterioles. Among the options provided, this is the most likely adverse effect.
- Other common adverse effects of non-dihydropyridine CCBs include **constipation** (especially with verapamil), **bradycardia**, and **AV block**.
*Bronchospasm*
- **Bronchospasm** is a common adverse effect of **beta-blockers** due to their blockade of β₂-adrenergic receptors in the airways.
- Calcium channel blockers do not cause bronchospasm and may actually have bronchodilatory effects.
*Dry mouth*
- **Dry mouth** is often associated with **anticholinergic medications** (e.g., tricyclic antidepressants, antihistamines) due to their inhibition of salivary secretions.
- This is not a characteristic adverse effect of calcium channel blockers.
*Tinnitus*
- **Tinnitus** (ringing in the ears) can be an adverse effect of various drugs, including **aspirin** (especially at high doses), **loop diuretics**, and some **aminoglycoside antibiotics**.
- It is not typically associated with calcium channel blockers.
*Gingival hyperplasia*
- **Gingival hyperplasia** is a well-known adverse effect of **dihydropyridine calcium channel blockers** (like nifedipine), as well as **phenytoin** and **cyclosporine**.
- While it can rarely occur with **non-dihydropyridine CCBs**, it is much less commonly associated with verapamil or diltiazem compared to dihydropyridines.
Question 75: An otherwise healthy 13-year-old boy is brought to the physician because of asthma attacks that have been increasing in frequency and severity over the past 4 weeks. He was first diagnosed with asthma 6 months ago. Current medications include high-dose inhaled fluticasone and salmeterol daily, with additional albuterol as needed. He has required several courses of oral corticosteroids. A medication is added to his therapy regimen that results in downregulation of the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Which of the following drugs was most likely added to the patient's medication regimen?
A. Infliximab
B. Theophylline
C. Zileuton
D. Nedocromil
E. Omalizumab (Correct Answer)
Explanation: ***Omalizumab***
- **Omalizumab** is a **monoclonal antibody** that targets and binds to free IgE, preventing its binding to **FcεRI receptors** on mast cells and basophils.
- By reducing free IgE, it leads to a **downregulation of FcεRI receptors**, thereby decreasing mediator release and reducing asthma symptoms in severe, persistent asthma.
*Infliximab*
- **Infliximab** is an **anti-TNF-α monoclonal antibody** used primarily in inflammatory conditions like **rheumatoid arthritis**, **Crohn's disease**, and **ankylosing spondylitis**.
- It does not directly affect IgE or its receptors, thus it is not indicated for the treatment of **asthma**.
*Theophylline*
- **Theophylline** is a **phosphodiesterase inhibitor** that causes bronchodilation by increasing intracellular cAMP.
- It does not modulate IgE or its receptors, and its use is limited by a narrow **therapeutic index** and potential for side effects.
*Zileuton*
- **Zileuton** is a **5-lipoxygenase inhibitor** that blocks the synthesis of **leukotrienes**, potent bronchoconstrictors and inflammatory mediators in asthma.
- While effective in some asthma patients, it does not act on IgE or its receptors.
*Nedocromil*
- **Nedocromil** is a **mast cell stabilizer** that inhibits the release of inflammatory mediators from mast cells.
- It does not directly impact IgE levels or the expression of **FcεRI receptors** on mast cells and basophils, making it less suitable for severe, refractory asthma requiring IgE-pathway modulation.
Question 76: A 64-year-old man presents to his physician 6 months after experiencing a myocardial infarction. The patient currently denies any symptoms and is only in for a check up. The patient's past medical history is notable for diabetes (type II), obesity, hypertension and cyclothymia. His current medications are hydrochlorothiazide, metoprolol, metformin, insulin, fluoxetine, and fish oil. On physical exam you note a calm elderly man who is moderately obese and in no current distress. The patient's cardiovascular exam is notable for a S4 heart sound. The patients lab work is below.
Serum:
Na+: 140 mEq/L
Cl-: 100 mEq/L
K+: 4.4 mEq/L
HCO3-: 23 mEq/L
BUN: 20 mg/dL
Glucose: 120 mg/dL
Creatinine: 1.6 mg/dL
Ca2+: 10.1 mg/dL
AST: 11 U/L
ALT: 9 U/L
Cholesterol: 190 mg/dL
Triglycerides: 150 mg/dL
High density lipoprotein associated cholesterol: 11 mg/dL
Low density lipoprotein associated cholesterol: 149 mg/dL
The physician updates the patient's medication regimen after this visit.
The patient returns 2 weeks later and presents his blood glucose diary to you demonstrating a mean blood glucose of 167 mg/dL. He is also complaining of flushing that occurs occasionally but otherwise is doing well. Which of the following is most likely to alleviate this patient's current symptom?
A. Irreversible inactivation of cyclooxygenase (Correct Answer)
B. Inhibition of angiotensin II formation
C. GLUT-4 insertion in cell membranes
D. Decreased inhibition of HMG CoA reductase
E. Discontinue diuretic that inhibits Na/Cl cotransporter
Explanation: ***Irreversible inactivation of cyclooxygenase***
- The patient is likely experiencing **flushing** due to **niacin** (nicotinic acid) therapy, which is often used to lower **LDL-C** and **triglycerides** and raise **HDL-C**. Niacin-induced flushing is mediated by **prostaglandins**, specifically **PGD2**, which can be alleviated by irreversible inactivation of COX with **aspirin**.
- Given his history of **myocardial infarction**, poorly controlled diabetes, and dyslipidemia (HDL-C of 11 mg/dL, LDL-C 149 mg/dL), a lipid-modifying agent like niacin would be a reasonable addition to his regimen.
*Inhibition of angiotensin II formation*
- This refers to the mechanism of **ACE inhibitors** or **ARBs**, which are used to manage hypertension and protect the kidneys, especially in patients with diabetes and post-MI.
- While beneficial for this patient's overall cardiovascular health, it does not directly address the symptom of **flushing**.
*GLUT-4 insertion in cell membranes*
- This mechanism is associated with **thiazolidinediones (TZDs)**, a class of antidiabetic drugs that improve **insulin sensitivity**.
- While improved glucose control (mean 167 mg/dL) is needed for this patient, GLUT-4 insertion does not alleviate flushing.
*Decreased inhibition of HMG CoA reductase*
- This response implies stopping or reducing the dose of a **statin**, which inhibits **HMG-CoA reductase** and is crucial for lowering LDL-C.
- The patient's LDL-C of 149 mg/dL is still elevated, and statins are a cornerstone of post-MI therapy; thus, decreasing their inhibition would be detrimental to his cardiovascular risk.
*Discontinue diuretic that inhibits Na/Cl cotransporter*
- The patient is currently on **hydrochlorothiazide**, which inhibits the **Na/Cl cotransporter** in the distal convoluted tubule and helps manage his hypertension.
- Discontinuing this medication would likely worsen his blood pressure and has no direct effect on flushing.
Question 77: A 50-year-old man presents to the emergency department for evaluation of a pulsatile headache, palpitations, chest pain, and anxiety. The vital signs include: heart rate 90/min, blood pressure 211/161 mm Hg, and respiration rate 18/min. His fundoscopic exam is remarkable for papilledema. An urgent urinalysis reveals increased protein and red blood cells (RBCs). Further evaluation reveals elevated plasma metanephrines. What is the 1st step in the definitive treatment of this patient’s underlying disorder?
A. Calcium channel blockers
B. Hydralazine
C. Beta-blockers followed by alpha-blockers
D. Emergent surgery
E. Alpha-blockers followed by beta-blockers (Correct Answer)
Explanation: ***Alpha-blockers followed by beta-blockers***
- This patient presents with symptoms highly suggestive of a **pheochromocytoma** (pulsatile headache, palpitations, chest pain, anxiety, severe hypertension, papilledema, and elevated plasma metanephrines). The first step in managing a pheochromocytoma, especially before surgery, is to start with **alpha-blockade** to control blood pressure and prevent a hypertensive crisis.
- After adequate alpha-blockade (typically for 7-14 days), **beta-blockers** can be added to control tachycardia and arrhythmias. Using beta-blockers before alpha-blockers can lead to unopposed alpha-adrenergic stimulation, causing a further rise in blood pressure.
*Calcium channel blockers*
- While calcium channel blockers can be used to manage hypertension, they are **not the primary or initial treatment** for a pheochromocytoma.
- They do not address the root cause of the catecholamine excess and are less effective in preventing a hypertensive crisis in this specific context.
*Hydralazine*
- Hydralazine is a **direct arterial vasodilator** and can be used in hypertensive emergencies.
- However, it is not the preferred initial agent for pheochromocytoma given the need for comprehensive alpha-blockade to manage the effects of excessive catecholamines.
*Beta-blockers followed by alpha-blockers*
- Administering **beta-blockers before alpha-blockers** in a patient with pheochromocytoma is contraindicated and dangerous.
- This sequence can lead to **unopposed alpha-adrenergic stimulation**, resulting in profound vasoconstriction and a life-threatening hypertensive crisis.
*Emergent surgery*
- While surgery is the definitive treatment for pheochromocytoma (removal of the tumor), it is **not the 1st step in treatment**.
- Proper **preoperative medical management** with alpha-blockade (and subsequent beta-blockade) is critical to stabilize the patient and prevent complications during surgery.
Question 78: A 26-year-old woman presents to the clinic with complaints of missing her 'monthlies'. She usually has her menses around the 15th of every month and they last for about 4 days. She is not on any birth control and has recently gotten into a relationship with her boyfriend from college. She is on lithium for maintenance therapy of her bipolar disorder. She once took herself off of lithium, but she became so depressed that she had a suicide attempt shortly after. She is concerned about how lithium use might affect her fetus if she were pregnant. What is the single most appropriate recommendation?
A. Supplement her treatment with 3-4 mg of folate per day.
B. The lithium should be discontinued immediately.
C. Discontinue the lithium after delivery and before breastfeeding.
D. Add another drug to the regime but decrease each drug’s dosage.
E. Continue her lithium monotherapy. (Correct Answer)
Explanation: ***Continue her lithium monotherapy.***
- Maintaining **lithium monotherapy** is crucial given her history of severe depression and suicide attempt when off lithium, prioritizing maternal mental health during pregnancy.
- While lithium carries some fetal risks (e.g., Ebstein's anomaly), these risks are dose-dependent and careful monitoring can mitigate them, justifying continued therapy over abrupt discontinuation.
*Supplement her treatment with 3-4 mg of folate per day.*
- While **folate supplementation** is generally recommended in pregnancy to prevent neural tube defects, it does not directly address the specific fetal risks associated with lithium exposure or the patient's need for mood stabilization.
- The standard dose for women with no previous affected pregnancies is 0.4-0.8mg daily. Higher doses are usually reserved for women with a history of neural tube defects or who are on **anti-epileptics**.
*The lithium should be discontinued immediately.*
- **Abrupt discontinuation** of lithium carries a very high risk of relapse into severe depression or mania, which could pose a significant danger to both the mother and the fetus.
- Given her history of a suicide attempt when off lithium, this action could lead to detrimental maternal mental health outcomes.
*Discontinue the lithium after delivery and before breastfeeding.*
- This recommendation addresses neither the immediate mental health needs during pregnancy nor the potential fetal exposure risks during the most critical developmental stages.
- Discontinuing lithium only after delivery and before breastfeeding still exposes the fetus to lithium throughout pregnancy, while also interrupting critical postpartum mood stability for the mother.
*Add another drug to the regime but decrease each drug’s dosage.*
- Adding another drug would introduce additional fetal exposure risks without clear evidence of benefit over carefully managed monotherapy, especially with a history of effective lithium use.
- **Polypharmacy** during pregnancy is generally avoided due to increased complexity and potential for drug interactions, and simply decreasing dosages might not maintain therapeutic levels.
Question 79: A 68-year-old man presents to his primary care physician with complaints of intermittent dysuria, pain with ejaculation, mild lower abdominal pain, and difficulty voiding for the last four months. There is no weight loss or change in stools. He has no known family history of cancer. His past medical history is notable for irritable bowel syndrome and hypertension. On examination, he is well-appearing but mildly uncomfortable. There are no abdominal or rectal masses appreciated; the prostate is mildly tender to palpation, but with normal size, texture, and contour. Urinalysis reveals trace leukocyte esterase and negative nitrite, negative blood, and no bacteria on microscopy. Which of the following is the most appropriate treatment?
A. Duloxetine
B. Finasteride
C. Ciprofloxacin
D. Tamsulosin and ciprofloxacin
E. Tamsulosin (Correct Answer)
Explanation: ***Tamsulosin***
- The patient's symptoms (dysuria, pain with ejaculation, difficulty voiding, lower abdominal pain) are suggestive of **chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)**, particularly in the absence of infection. **Alpha-blockers like tamsulosin** relax smooth muscle in the prostate and bladder neck, improving urinary flow and reducing pain.
- The **mildly tender prostate** and **urinalysis showing trace leukocyte esterase but negative nitrites and bacteria** rule out acute bacterial prostatitis and indicate inflammation without overt infection, strengthening the diagnosis of CP/CPPS.
*Duloxetine*
- This medication is a **serotonin-norepinephrine reuptake inhibitor (SNRI)**, primarily used for depression, anxiety, and neuropathic pain.
- While CP/CPPS can involve neuropathic-like pain, duloxetine is **not a first-line treatment** and does not address the underlying urinary flow issues.
*Finasteride*
- **Finasteride is a 5-alpha-reductase inhibitor** used to treat **benign prostatic hyperplasia (BPH)** by reducing prostate size.
- The patient's prostate is described as having **normal size, texture, and contour**, making BPH less likely as the primary cause of his symptoms, and finasteride would not directly relieve the inflammatory or ejaculatory pain.
*Ciprofloxacin*
- **Ciprofloxacin is an antibiotic** effective against many urinary pathogens.
- However, the **urinalysis showed negative nitrites and no bacteria on microscopy**, making a bacterial infection (acute or chronic bacterial prostatitis) unlikely. Therefore, empirical antibiotic monotherapy is not indicated.
*Tamsulosin and ciprofloxacin*
- While tamsulosin is appropriate, the addition of **ciprofloxacin is not justified** given the lack of evidence for bacterial infection (negative nitrites and no bacteria on microscopy).
- Combining these would expose the patient to unnecessary antibiotic side effects without clear benefit for an infection that doesn't appear to be present.
Question 80: A 75-year-old man with a seizure disorder is brought to the emergency department by a friend because of progressive confusion over the past two weeks. He is unable to provide any history. His vital signs are within normal limits. He appears lethargic and is only oriented to person. Oral mucosa is moist. There is no jugular venous distention. A basic metabolic panel shows a serum sodium concentration of 115 mEq/L but is otherwise normal. Serum osmolality is low and antidiuretic hormone level is elevated. X-ray of the chest shows no abnormalities. Which of the following is the most likely cause of this patient’s hyponatremia?
A. Aldosterone deficiency
B. Medication effect (Correct Answer)
C. Low cardiac output
D. Insulin deficiency
E. Excess cortisol
Explanation: ***Medication effect***
- This patient's **hyponatremia** with **appropriately low serum osmolality** and **elevated antidiuretic hormone (ADH)** levels, in the absence of signs of hypovolemia or fluid overload, points to the **syndrome of inappropriate ADH secretion (SIADH)**.
- Many medications, including anti-epileptic drugs like carbamazepine or oxcarbazepine (commonly used for seizure disorders), as well as selective serotonin reuptake inhibitors (SSRIs), can cause SIADH.
*Aldosterone deficiency*
- **Aldosterone deficiency** would likely lead to **hyperkalemia** and metabolic acidosis, which are not mentioned in the basic metabolic panel as being abnormal.
- While it can cause hyponatremia due to inability to retain sodium, the elevated ADH level with normal volume status points away from primary aldosterone deficiency.
*Low cardiac output*
- **Low cardiac output** can lead to hyponatremia by decreased renal perfusion and activation of the renin-angiotensin-aldosterone system and ADH release.
- However, this patient has **normal vital signs** and **no jugular venous distention**, making significant low cardiac output and resultant hypovolemia less likely.
*Insulin deficiency*
- **Insulin deficiency** (as seen in uncontrolled diabetes) typically leads to **hyperglycemia** and can cause a **pseudohyponatremia** due to osmotic effects, or true hyponatremia due to polyuria and volume depletion.
- The basic metabolic panel is otherwise normal, suggesting no significant hyperglycemia or electrolyte abnormalities consistent with insulin deficiency.
*Excess cortisol*
- **Excess cortisol** (Cushing's syndrome) typically leads to **hyperglycemia**, hypertension, and features of fat redistribution, muscular weakness, and thin skin, none of which are detailed here.
- It does not directly cause hyponatremia; conversely, cortisol has some mineralocorticoid effects and typically opposes ADH action, so severe excess would more likely cause hypernatremia or normal sodium levels.